Cordes Lisa M, Gulley James L, Madan Ravi A
aClinical Center, National Institutes of Health, Bethesda bGenitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Curr Opin Oncol. 2016 May;28(3):232-40. doi: 10.1097/CCO.0000000000000281.
In recent clinical trials, immunotherapeutic agents have demonstrated promising results for the treatment of prostate cancer. This review discusses emerging immunotherapies for prostate cancer and their evolving role in sequencing and combination therapy.
Therapeutic vaccines including PROSTVAC and DCVAC/PCa have completed promising phase 2 trials for the treatment of prostate cancer and phase 3 trials are underway. Recent evidence supports a synergistic relationship between immunotherapy agents themselves, antiandrogens and with cytotoxic chemotherapy. Prostate cancer patients with good prognostic factors, such as minimal disease burden, appear to achieve the optimal benefit from immunotherapy.
Therapeutic cancer vaccines and immunomodulating agents have demonstrated activity in the treatment of prostate cancer. Immunotherapies may alter the prostate tumor microenvironment and ongoing studies aim to provide guidance on effective sequencing and combination strategies.
在最近的临床试验中，免疫治疗药物已显示出治疗前列腺癌的良好前景。本综述讨论了前列腺癌新兴免疫疗法及其在序贯治疗和联合治疗中不断演变的作用。
包括PROSTVAC和DCVAC/PCa在内的治疗性疫苗已完成治疗前列腺癌的有前景的2期试验，3期试验正在进行中。最近的证据支持免疫治疗药物之间、抗雄激素药物与细胞毒性化疗之间存在协同关系。具有良好预后因素（如疾病负担最小）的前列腺癌患者似乎能从免疫治疗中获得最佳益处。
治疗性癌症疫苗和免疫调节药物已显示出治疗前列腺癌的活性。免疫疗法可能会改变前列腺肿瘤微环境，正在进行的研究旨在为有效的序贯治疗和联合治疗策略提供指导。
